Meet the Top 50 Social Influencers in BioTech and BioPharma
Few industries are as willing to take as steep risks on new technologies as the biotechnology and biopharmaceutical industries. Companies invest millions, and even billions, developing first-in-class drugs and devices that may one day cure, treat or manage pain caused by AIDS, cancer or any number of diseases.
Yet, when it comes to adopting social media, these industries have proven to be risk adverse. A recent study entitled “Engaging Patients Through Social Media” found that only 10 of the top 50 pharmaceutical companies in the world use all three of the top social media channels – Facebook, Twitter and YouTube — for communicating about healthcare topics. We believe this reticence is largely due to regulatory concerns and the potential high cost of a social media misstep, as well as the rapid pace of innovation, intense competition, and emphasis on proprietary products.
In a first step towards bringing the community together to have meaningful social conversations on the topics of biotech and biopharma innovation and investing, Evolve was commissioned by biopharmaceutical company NEMUS Bioscience, Inc., (OTCQB: NMUS) to identify the Top 30 Social Influencers in Biotech and Biopharma.
The ranking measures the online impact of more than 400 of the most knowledgeable, most influential, and most social thought leaders, doctors, scientists, academics, analysts, investors and patient advocates in the biopharma and biotech fields. Evolve compiled the list of candidates using a broad range of influencer discovery and engagement tools, including Little Bird, Group High, Google and researching the top biotech and biopharma Twitter users identified by industry insiders. All candidates were vetted for their topical influence and scored based on measurables such as social footprint, popularity among and citations by industry insiders, retweet frequency and related factors. Weights were assigned to each factor to pinpoint the top 50 social thought leaders.
Follow the Top 50 social influencers in a single click.
An alphabetical listing of 20 social biotech and biopharma influencers rounds out the top 50 list, below.
|Alex Butler||Managing Director||The EarthWorks||Alex__Butler|
|Kevin Davies||Founding Editor||Nature Genetics||KevinADavies|
|Anna Edney||FDA Reporter||Bloomberg News||annaedney|
|Dr. Tom Ellis||Senior Lecturer in Synthetic Biology||Imperial College London||DrTomEllis|
|Ian Estepan||Healthcare Portfolio Manager||ianestepan|
|Ben Fidler||Deputy Biotechnology Editor||Xconomy||benthefidler|
|Erika Check Hayden||Journalist and Educator||Scientific American||erika_check|
|Ben Hirschler||Pharma, Health and Science Writer||Reuters||reutersBenHir|
|Derek Lowe||Drug Discovery Chemist and Blogger, Research Fellow||Vertex Pharmaceuticals||Dereklowe|
|John Mack||Pharma Marketing Blogger||Pharma Marketing Blog||pharmaguy|
|Marilynn Marchione||Health Writer||Associated Press||MMarchioneAP|
|Jason Napodano, CFA||Senior Biotech Analyst||Zacks Investment Research||JNapodano|
|Jonathan Rockoff||Reporter covering pharmaceutical and biotech industries||The Wall Street Journal||jonathanrockoff|
|Cheryl Shuman||CEO||Cheryl Shuman PR Marketing; Executive Director, Moms for Marijuana||CherylShuman|
|Tara C Smith, PhD||Professor, Researcher, Writer & Science Blogger||Smith Emerging Infections Laboratory, Kent State University||aetiology|
|Serena Stockwell||Editor||Oncology Times||oncologytimes|
|Luke Timmerman||Biotech Journalist||Independent||ldtimmerman|
|Anas Younes, M.D.||Chief of Lymphoma Service||Memorial Sloan Kettering Cancer Center||dranasyounes|
The most powerful social influencers in the industry stood out for their insight, reach, information and ability to drive the conversation about the most important advances, moves and people in biotech and biopharama.
The top spot in our list went to Evercore ISI Managing Partner Mark Schoenebaum, MD, who remarkably saw an average 18,000 Twitter responses to each of his tweets during the first half of 2014. According to Schoenebaum, social media can be an effective tool for soliciting early feedback on breaking news such as clinical data from a variety of stakeholders, including physicians, companies and analysts. New York Times science and technology reporter and two-time Pulitzer Prize winner Amy Harmon and NYU clinical assistant professor Scott Gottlieb round out the top three spots. Collectively, these individuals represent the analyst, medical, press and academic communities — four of the key constituents leading the social biotech conversation. Tom Frieden, Director of the CDC and Biocon managing director Kiran Mazumdar-Shaw checked in as the highest ranking government and healthcare influencers respectively.
Of course, Evolve’s ranking is not the final word on the subject but rather the beginning of a discussion. What factors will impact the rate of using social technologies to engage with the biotech and biopharma community in the future? Please share your thoughts.
[4:46:59 PM] Jenna Dobkin: Disclosure, The author does not have an ownership position in NEMUS BioScience, Inc. (OTCQB: NMUS)